a1-Antichymotrypsin, Human (AACT, Alpha1-ACT)

Alpha 1 ACT is an early-stage acute-phase plasma protein and a serpin that preferentially inactivates chymotrypsin, cathepsin G, and chymase. Alpha-1- ACT, a serine protease inhibitor, is tightly associated with amyloid plaques in Alzheimer's disease (AD) and in normal aged human and monkey brain. Regulation of the serine proteases and serine protease inhibitors plays an important role in neuromuscular differentiation. Prostate specific antigen (PSA), a chymotrypsin-like serine protease, is predominantly complexed to Alpha-1-ACT.\n\nApplications: \n

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

A2298-03A

Size

20ug

Form

Supplied as a liquid in 50mM Tris-acetate, pH 7.5, 1mM EDTA and 20% glycerol.

References

1. Post-stroke dementia is associated with alpha(1)-antichymotrypsin polymorphism. J Neurol Sci 2005 Jul 15;234(1-2):31-6 2. Alpha-1-antichymotrypsin gene polymorphism and susceptibility to multiple system atrophy (MSA). Brain Res Mol Brain Res 2005 Aug 18;138(2):178-81 3. Duration of alpha 1-antichymotrypsin gene activation by interleukin-1 is determined by efficiency of inhibitor of nuclear factor kappa B alpha resynthesis in primary human astrocytes. J Neurochem 2005 Feb;92(4):730-8 4. A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease. Neurobiol Aging 2005 Apr;26(4):449-53 5. mRNA expression level of estrogen-inducible gene, alpha 1-antichymotrypsin, is a predictor of early tumor recurrence in patients with invasive breast cancers. Cancer Sci 2004 Nov;95(11):887-92 6. Allele-specific overexpression in astrocytes of an Alzheimer's disease associated alpha-1-antichymotrypsin promoter polymorphism. Brain Res Mol Brain Res 2004 Nov 24;131(1-2):88-92